3-Benzoylpropionic acidCAS# 2051-95-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products

Cas No. | 2051-95-8 | SDF | Download SDF |
PubChem ID | 72871 | Appearance | Powder |
Formula | C10H10O3 | M.Wt | 178.19 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Synonyms | 4-Oxo-4-Phenylbutanoic Acid; 4-Oxo-4-Phenylbutyric Acid | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 4-oxo-4-phenylbutanoic acid | ||
SMILES | C1=CC=C(C=C1)C(=O)CCC(=O)O | ||
Standard InChIKey | KMQLIDDEQAJAGJ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C10H10O3/c11-9(6-7-10(12)13)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,12,13) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |

3-Benzoylpropionic acid Dilution Calculator

3-Benzoylpropionic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.612 mL | 28.0599 mL | 56.1199 mL | 112.2397 mL | 140.2997 mL |
5 mM | 1.1224 mL | 5.612 mL | 11.224 mL | 22.4479 mL | 28.0599 mL |
10 mM | 0.5612 mL | 2.806 mL | 5.612 mL | 11.224 mL | 14.03 mL |
50 mM | 0.1122 mL | 0.5612 mL | 1.1224 mL | 2.2448 mL | 2.806 mL |
100 mM | 0.0561 mL | 0.2806 mL | 0.5612 mL | 1.1224 mL | 1.403 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland

TsingHua University

The University of Michigan

Miami University

DRURY University

Jilin University

Fudan University

Wuhan University

Sun Yat-sen University

Universite de Paris

Deemed University

Auckland University

The University of Tokyo

Korea University
- Fmoc-Tyr(HPO3Bzl)-OH
Catalog No.:BCC3565
CAS No.:191348-16-0
- Ursolic aldehyde
Catalog No.:BCN7712
CAS No.:19132-81-1
- 6-Deoxy-3-O-methyl-beta-allopyranosyl(1-4)-beta-cymaronic acid delta-lactone
Catalog No.:BCN1514
CAS No.:19131-13-6
- 1-Deoxynojirimycin
Catalog No.:BCN1032
CAS No.:19130-96-2
- Boc-Asp(OtBu)-OH.DCHA
Catalog No.:BCC3369
CAS No.:1913-12-8
- C 75
Catalog No.:BCC2386
CAS No.:191282-48-1
- YM 976
Catalog No.:BCC7190
CAS No.:191219-80-4
- Pramipexole 2HCl Monohydrate
Catalog No.:BCC4466
CAS No.:191217-81-9
- Solasonine
Catalog No.:BCN2302
CAS No.:19121-58-5
- Atrazine
Catalog No.:BCC8838
CAS No.:1912-24-9
- Telithromycin
Catalog No.:BCC5273
CAS No.:191114-48-4
- Oplopanone
Catalog No.:BCN1179
CAS No.:1911-78-0
- AGN 195183
Catalog No.:BCC5419
CAS No.:191469-29-1
- LY 379268
Catalog No.:BCC7368
CAS No.:191471-52-0
- Isoficusin A
Catalog No.:BCN6865
CAS No.:1914963-20-4
- 2-Hydroxyxanthone
Catalog No.:BCN7545
CAS No.:1915-98-6
- Epieriocalyxin A
Catalog No.:BCN1180
CAS No.:191545-24-1
- 2-Deacetoxytaxinine B
Catalog No.:BCN1181
CAS No.:191547-12-3
- Trimethylgallic acid methyl ester
Catalog No.:BCN3369
CAS No.:1916-07-0
- SIB 1553A hydrochloride
Catalog No.:BCC6284
CAS No.:191611-89-9
- Pomalidomide (CC-4047)
Catalog No.:BCC2246
CAS No.:19171-19-8
- Tenacissoside G
Catalog No.:BCN4682
CAS No.:191729-43-8
- Tenacissoside I
Catalog No.:BCN4681
CAS No.:191729-44-9
- Tenacissoside H
Catalog No.:BCN2570
CAS No.:191729-45-0
Structure-activity studies of 3-benzoylpropionic acid derivatives suppressing adjuvant arthritis.[Pubmed:1611693]
Chem Pharm Bull (Tokyo). 1992 Mar;40(3):774-7.
3-Benzoylpropionic acid derivatives possess an immunomodulative activity and suppress adjuvant arthritis. To understand how substituents affect the biological activity, the quantitative structure-activity relationships of 30 compounds were analyzed by the adaptive least-squares method. For the suppressing activity in rats, the electronic effects and the structural feature of the substituent on benzene ring were suggested to be important. To reinforce and confirm the correlation, 4 additional compounds of phenoxybutyric acid derivatives were synthesized and tested with the rat adjuvant-induced arthritis. These compounds were found to have potent suppressing activity.